Scientists from Sanford Burnham Prebys have created natural-looking hair that grows through the skin using human induced pluripotent stem cells (iPSCs), a major scientific achievement that could revolutionize the hair growth industry.
The findings were presented today at the annual meeting of the International Society for Stem Cell Research (ISSCR) and received a Merit Award. A newly formed company, Stemson Therapeutics, has licensed the technology.
More than 80 million men, women and children in the United States experience hair loss. Genetics, aging, childbirth, cancer treatment, burn injuries and medical disorders such as alopecia can cause the condition. Hair loss is often associated with emotional distress that can reduce quality of life and lead to anxiety and depression.
“Our new protocol described today overcomes key technological challenges that kept our discovery from real-world use,” says Alexey Terskikh, Ph.D., an associate professor in Sanford Burnham Prebys’ Development, Aging and Regeneration Program and the co-founder and chief scientific officer of Stemson Therapeutics. “Now we have a robust, highly controlled method for generating natural-looking hair that grows through the skin using an unlimited source of human iPSC-derived dermal papilla cells. This is a critical breakthrough in the development of cell-based hair-loss therapies and the regenerative medicine field.”
Terskikh studies a type of cell called dermal papilla. Residing inside the hair follicle, these cells control hair growth, including hair thickness, length and growth cycle. In 2015, Terskikh successfully grew hair underneath mouse skin (subcutaneous) by creating dermal papilla derived from human pluripotent stem cells—a tantalizing but uncontrolled process that required further refinement.
The approach detailed in the ISSCR presentation, which was delivered by lead researcher Antonella Pinto, Ph.D., a postdoctoral researcher in the Terskikh lab, features a 3D biodegradable scaffold made from the same material as dissolvable stitches. The scaffold controls the direction of hair growth and helps the stem cells integrate into the skin, a naturally tough barrier. The current protocol relies on mouse epithelial cells combined with human dermal papilla cells. The experiments were conducted in immunodeficient nude mice, which lack body hair.
The derivation of the epithelial part of a hair follicle from human iPSCs is currently underway in the Terskikh lab. Combined human iPSC-derived epithelial and dermal papilla cells will enable the generation of entirely human hair follicles, ready for allogenic transplantation in humans. Distinct from any other approaches to hair follicle regeneration, human iPSCs provide an unlimited supply of cells and can be derived from a simple blood draw.
“Hair loss profoundly affects many people’s lives. A significant part of my practice involves both men and women who are seeking solutions to their hair loss,” says Richard Chaffoo, M.D., F.A.C.S., a triple board-certified plastic surgeon who founded La Jolla Hair MD and is a medical adviser to Stemson Therapeutics. “I am eager to advance this groundbreaking technology, which could improve the lives of millions of people who struggle with hair loss.”
The technology was discovered and developed at Sanford Burnham Prebys. Further development and commercialization activities will be conducted by Stemson Therapeutics. For updates on the technology’s progress and advancement, please visit www.stemsontx.com.
Learn more: Functional hair follicles grown from stem cells
The Latest on: Induced pluripotent stem cells
via Google News
The Latest on: Induced pluripotent stem cells
- Global Stem Cells Market 2019 Industry Analysis, Size, Share, Growth by 2024 - Market Research Engineon August 16, 2019 at 10:28 am
The global stem cells market is expected to grow at an incredible CAGR of 25.5% from 2018 to 2024 and reach a market value of US$ 467 billion by 2024. The emergence of Induced Pluripotent Stem (iPS) ...
- mRNA and miRNA expression profiles in an ectoderm-biased substate of human pluripotent stem cellson August 15, 2019 at 3:35 am
and differentiated cells from embryonic stem (ES) cells and induced pluripotent stem (iPS) cells 1,2,3. In particular, both ES cells and iPS cells have broad applications in various disease states 2,3 ...
- Simple protocol for assessing maturation of HPCs from induced pluripotent stem cellson August 14, 2019 at 8:49 am
Researchers have developed a guide to help labs standardize the production of mature hepatic-like cells (HPCs) from stem cells and easily compare gene expression of HPCs to actual human liver tissue.
- New nanotechnology could aid stem cell transplantation researchon August 14, 2019 at 3:24 am
Stem cells can develop into many different types of cells, including neurons that transmit information in the brain. Adult human-induced pluripotent stem cells, which resemble embryonic stem cells ...
- Bayer To Buy Out Stem Cell Therapy Company BlueRock For Up To $600Mon August 9, 2019 at 4:01 pm
Why It's Important BlueRock's cell therapy portfolio focuses on neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell, or iPSC platform. It has a lead program in ...
- Bayer buys BlueRock in $600 million bet on stem cell therapieson August 8, 2019 at 4:39 am
BlueRock, valued at about $1 billion by the deal, is working on induced pluripotent stem cells (iPSC), made by reprogramming mature body cells to behave like embryonic stem cells that are injected to ...
- New method to enhance heart-attack repair using stem cell-derived cardiomyocyteson August 7, 2019 at 10:24 pm
... not suitable for cell transplantation and have to be removed from cell preparations. The researchers found they could activate transcription factor p53 in induced pluripotent stem cells to ...
- Stem cell treatment may reverse heart attack damageon August 6, 2019 at 9:08 am
"To our knowledge," the researchers said in a press release, "this is the first study to show that DNA damage-free induced pluripotent stem cells can be selected by p53 activation in induced ...
- A simple method to improve heart-attack repair using stem cell-derived heart muscle cellson August 6, 2019 at 6:29 am
The researchers found they could activate transcription factor p53 in induced pluripotent stem cells to selectively induce programmed cell death, or apoptosis, specifically in DNA-damaged cells ...
via Bing News